Infrastructure equity capabilities 'jewel' in River and Mercantile crown

Led by Ian Berry

James Baxter-Derrington
clock • 1 min read

River and Mercantile’s recently formed infrastructure investment capability is the “jewel” of the business, according AssetCo deputy chair Peter McKellar.

Speaking on a wire call following the news that AssetCo's all-share acquisition representing a £98.8m sale had been accepted, McKellar said while the firm was "delighted" with the entire purchase of RMG's asset management business, he highlighted the Ian Berry-led infrastructure arm. Berry joined the group in January 2021 after more than a decade at Aviva Investors and brought a number of colleagues with him to establish the business. McKellar particularly noted the team's investment in UK renewable infrastructure, which he described as offering a "high income infrastructure opportuni...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
European private equity yet to spend €270bn worth of capital

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Early-stage biopharma: An opportunity for strategic investment

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot